Luye Pharma Group i aso nei na faasilasila mai o lana lala o Luye Pharma Switzerland AG ua osia maliega ma Exeltis Pharma México, SA de CV ma Exeltis Pharmaceuticals Holding, SL (Exeltis), lea e tuʻuina atu ai e le kamupani le aia tatau a Exeltis e faʻatau ai Rivastigmine Multi-Day Transdermal Patch. (Rivastigmine MD) i Mekisiko ma Polani.

Rivastigmine MD ose fa'asologa fa'afouga fa'alua-vaiaso o le Rivastigmine mo le togafitia o le tu'inanau vaivai ma le feololo e feso'ota'i ma le fa'ama'i o le Alzheimer. O le vailaʻau na atiaʻe e Luye Pharma i luga o lona faʻamaufaʻailogaina transdermal patch platform ma ua maua le faʻatagaina o maketi mo le tele o atunuu Europa.

Bruno Delie, Pule Sili o Luye Pharma (Switzerland), fai mai: "Exeltis o loʻo i ai se faʻasalalauga faʻasalalauga faʻapitoa ma le tamaoaiga o le poto ma le tomai i le ogatotonu o le tino (CNS) eria togafitiga. Matou te tulimatai atu e galulue vavalalata ma Exeltis e faʻatalanoa manaʻoga e leʻi faʻataunuʻuina o le faʻatupulaia o nuʻu gasegase o le Alzheimer, ma fesoasoani ia i latou e pulea lelei le faʻamaʻi. I le avea ai ma se vaega o le Insud Pharma Group, lea o loʻo faʻauluulu i Sepania, o Exeltis o se kamupani faʻatau vailaʻau faʻavaomalo ma oloa o loʻo faʻatau atu nei i atunuu e 44 i le salafa o le lalolagi. O loʻo iai le poto masani a le kamupani i faʻamaʻi CNS ma faʻatautaia pisinisi malosi i Europa ma LatAm.

Luye Pharma o loʻo faʻavaveina le atinaʻeina ma le faʻasalalauga o Rivastigmine MD i le maketi o le lalolagi. O fa'atauga i maketi i Europa o lo'o ufiufi e pa'aga ma pa'aga a le kamupani. I le taimi nei, o aia tatau tau atinaʻe ma fefaʻatauaʻiga mo Rivastigmine MD i Iapani ua tuʻuina atu i se paaga Iapani. Luye Pharma foi o loʻo fuafua e faʻavavevave le maketiina o Rivastigmine MD i le tele o atunuʻu atinaʻe ma maketi faʻalauiloa i le lalolagi atoa.

O le fa'ama'i o le Alzheimer ose ma'i neurodegenerative e le mafai ona toe fa'afo'isia lea e fa'atupu ai le fa'aitiitia o le mafaufau ma isi vaega o le mafaufau. Dementia e fesoʻotaʻi ma le faʻamaʻi o le Alzheimer o le tuʻufaʻatasiga masani lea o le tuinanau, e tusa ma le 60-80% o mataupu uma [i]. O loʻo faʻatatauina e sili atu i le 50 miliona tagata o loʻo nonofo i le tuinanau i le lalolagi atoa, o se fuainumera ua faʻatulagaina e sili atu i le faatolu, i le 152 miliona i le 2050[ii].

O le alualu i luma o le atinaʻeina o vailaʻau fou i le faʻamaʻi o le Alzheimer e fai si tuai, ma i le taimi nei e naʻo se numera faʻatapulaʻa o togafitiga faʻapitoa e avanoa mo gasegase. O le Rivastigmine ose vaila'au muamua i le togafitiga o le tu'inanau e feso'ota'i ma le fa'ama'i o le Alzheimer ma o lo'o fa'atau atu nei i le lalolagi atoa.

OA MEA E AVEA MAI LENEI TUSI:

Progression of new drug development in the field of Alzheimer’s disease is relatively slow, and at present there are only a very limited number of therapeutic options available to patients.
Luye Pharma also plans to accelerate the marketing of Rivastigmine MD in a number of developing countries and emerging markets around the world.
Rivastigmine is a first-line drug in the treatment of dementia associated with Alzheimer’s disease and is currently marketed worldwide.